Psilocybin in palliative care — the research and ethical considerations

The original studies (NYU 2016, Hopkins 2016) found that a single high-dose psilocybin session produced significant reductions in death anxiety, depression, and meaninglessness in cancer patients facing life-threatening illness. Effects were maintained at 6-month follow-up in 80% of participants. The quality of these results — and this population — is arguably the strongest evidence for psilocybin-assisted therapy. People near death have little to lose and significant suffering to address.

Current state (2025): multiple ongoing trials, including Hopkins and UCSF, with life-limiting illness patients. COMPASS Pathways has palliative applications in their pipeline. Some hospice organizations are quietly facilitating access for terminal patients who want it and cannot wait for clinical trials. The FDA has granted breakthrough therapy designation for depression, which will likely accelerate palliative applications.

Ethical considerations specific to this population: (1) capacity to consent — cognitive impairment from illness or medication must be assessed; (2) timing — sessions should not be so close to death that integration is impossible; (3) caregiver and family involvement may be appropriate and beneficial; (4) the goal is quality of life, not longevity — this reframing is important for how sessions are prepared and integrated. Palliative psilocybin therapy is arguably the clearest ethical case for clinical access.